RIPK3 and viral infectious disease: Nec-1 treatment can mitigate the HL caused by cisplatin and kanamycin [120], can protect HCs from damage by cisplatin [121], TM [117], and virus infections [125], and can protect SGNs from damage by ouabain and RIPK3 overexpression [122].